BioStone > Veterinary Biologics and Vaccine Solutions

Veterinary Biologics and Vaccine Solutions

BioStone Animal Health’s acquisition of American Animal Health (AAH) assets and USDA-licensed facility has expanded BioStone’s capabilities in veterinary biologics manufacturing.

Built on AAH’s 40-year legacy of supporting livestock producers through commercial bacterin-toxoids and autogenous bacterins, BioStone is continuing that tradition through USDA-authorized biologics manufacturing and development.

Our current focus includes autogenous bacterin manufacturing services, Mannheimia haemolytica (MH) bacterin-toxoid opportunities, vaccine diluent partnership programs, vaccine antigens, and adjuvants.

BioStone is actively seeking veterinary partners, distributors, and vaccine manufacturing collaborators to expand access to innovative biologics solutions.